Grover Sandeep, Avasthi Ajit, Sharma Yogesh
Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh 160012, India.
Indian J Med Res. 2006 Apr;123(4):497-512.
With increase in the use of newer psychotropics, there is a growing concern in relation to the teratogenicity. Unfortunately, it is not possible to carry out prospective studies in pregnant women and as a result physicians caring for such patients have to rely on case reports, case series, and retrospective studies. Available evidence shows that the safety of psychotropics in pregnancy is still unresolved and the decision to prescribe psychotropics in pregnancy should be taken in the light of severity of mental disease, and drugs should be prescribed only when the potential risk to the foetus from exposure is outweighed by the risk of untreated maternal disorder. In this review we discussed the current evidence of the teratogenic risks with psychotropic drugs commonly used to treat psychiatric disorders and also focused on decision making in such patients.
随着新型精神药物使用的增加,人们对其致畸性的担忧日益增加。不幸的是,无法在孕妇中进行前瞻性研究,因此,照顾此类患者的医生不得不依赖病例报告、病例系列和回顾性研究。现有证据表明,精神药物在孕期的安全性仍未明确,孕期开具精神药物的决定应根据精神疾病的严重程度做出,只有当胎儿暴露于药物的潜在风险被未治疗的母体疾病风险超过时,才应开具药物。在本综述中,我们讨论了常用于治疗精神疾病的精神药物致畸风险的当前证据,并重点关注此类患者的决策制定。